• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910).
  
• Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910).
  
• Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Heterozygous (PubMed=29444910).
  
• Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1960Tyr (c.5879G>A); ClinVar=VCV000038003; Zygosity=Heterozygous (PubMed=29444910).
  
• Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910).
  
• Mutation; HGNC; 12363; TSC2; Simple; p.Arg1329His (c.3986G>A); ClinVar=VCV000041738; Zygosity=Unspecified (PubMed=25612765).
  

PubMed=1712329; DOI=10.5555/uri:pii:0016508591900045
Evers B.M., Townsend C.M. Jr., Upp J.R. Jr., Allen E., Hurlbut S.C., Kim S.W., Rajaraman S., Singh P., Reubi J.-C., Thompson J.C.
Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth.
Gastroenterology 101:303-311(1991)

PubMed=7978888; DOI=10.1111/j.1749-6632.1994.tb17289.x
Evers B.M., Ishizuka J., Townsend C.M. Jr., Thompson J.C.
The human carcinoid cell line, BON. A model system for the study of carcinoid tumors.
Ann. N. Y. Acad. Sci. 733:393-406(1994)

PubMed=8108375; DOI=10.1097/00006676-199401000-00013
Parekh D., Ishizuka J., Townsend C.M. Jr., Haber B., Beauchamp R.D., Karp G., Kim S.W., Rajaraman S., Greeley G.H. Jr., Thompson J.C.
Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion.
Pancreas 9:83-90(1994)

PubMed=19295186; DOI=10.1159/000209330
Siddique Z.-L., Drozdov I., Floch J., Gustafsson B.I., Stunes K., Pfragner R., Kidd M., Modlin I.M.
KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model.
Neuroendocrinology 89:458-470(2009)

PubMed=22538498; DOI=10.1159/000338793
Grozinsky-Glasberg S., Shimon I., Rubinfeld H.
The role of cell lines in the study of neuroendocrine tumors.
Neuroendocrinology 96:173-187(2012)

PubMed=22929519; DOI=10.3791/4218; PMCID=PMC3486771
Wong C., Vosburgh E., Levine A.J., Cong L., Xu E.Y.
Human neuroendocrine tumor cell lines as a three-dimensional model for the study of human neuroendocrine tumor therapy.
J. Vis. Exp. 66:e4218.1-e4218.7(2012)

PubMed=25612765; DOI=10.1530/JME-14-0304
Vandamme T., Peeters M., Dogan F., Pauwels P., Van Assche E., Beyens M., Mortier G., Vandeweyer G., de Herder W., Van Camp G., Hofland L.J., Op de Beeck K.
Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1.
J. Mol. Endocrinol. 54:137-147(2015)

PubMed=26087898; DOI=10.1016/j.cancergen.2015.04.002
Boora G.K., Kanwar R., Kulkarni A.A., Pleticha J., Ames M., Schroth G.P., Beutler A.S., Banck M.S.
Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Cancer Genet. 208:374-381(2015)

PubMed=29330294; DOI=10.1158/1541-7786.MCR-17-0163
Benten D., Behrang Y., Unrau L., Weissmann V., Wolters-Eisfeld G., Burdak-Rothkamm S., Stahl F.R., Anlauf M., Grabowski P., Mobs M., Dieckhoff J., Sipos B., Fahl M., Eggers C., Perez D., Bockhorn M., Izbicki J.R., Lohse A.W., Schrader J.
Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model.
Mol. Cancer Res. 16:496-507(2018)

PubMed=29444910; DOI=10.1530/ERC-17-0445; PMCID=PMC5827037
Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R., Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Endocr. Relat. Cancer 25:367-380(2018)

PubMed=29895527; DOI=10.1530/ERC-18-0159; PMCID=PMC7439002
Aristizabal Prada E.T., Spottl G., Maurer J., Lauseker M., Koziolek E.J., Schrader J., Grossman A., Pacak K., Beuschlein F., Auernhammer C.J., Nolting S.
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.
Endocr. Relat. Cancer 25:893-908(2018)

CLPUB00598
Behrang Y.
Establishment and characterization of a new human, highly differentiated and functionally active tumor model of a pancreatic neuroendocrine tumor.
Thesis MD (2020); University of Hamburg; Hamburg; Germany

PubMed=32884006; DOI=10.1038/s41598-020-71516-7; PMCID=PMC7471701
Monazzam A., Li S.-C., Wargelius H., Razmara M., Bajic D., Mi J., Bergquist J., Crona J., Skogseid B.
Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout BON1 cells: a human pancreatic neuroendocrine cell line.
Sci. Rep. 10:14572-14572(2020)